Are the effects of nicotinic acid on insulin resistance precipitated by abnormal phosphorous metabolism?

Lipids in Health and Disease

Hatem S AbuSabha¹  Moutasim H Al-Shaer¹ 

[1] The Department of Internal Medicine and Human Cardiovascular Physiology Laboratory University of Iowa College of Medicine Iowa City, Iowa 52242-1009, USA

关键词: Hypercholesterolemia;    Hyperlipidemia;    Dyslipidemia;    metabolic syndrome;    diabetes;    carbohydrate metabolism;    Insulin resistance;    Nicotinic acid;    Phosphorous;   

Others  :  1213282
DOI  :  10.1186/1476-511X-3-23

 received in 2004-10-14, accepted in 2004-10-28,  发布年份 2004

【 摘 要 】

Nicotinic acid is a unique cholesterol modifying agent that exerts favorable effects on all cholesterol parameters. It holds promise as one of the main pharmacological agents to treat mixed dyslipidemia in metabolic syndrome and diabetic patients. The use of nicotinic acid has always been haunted with concerns that it might worsen insulin resistance and complicate diabetes management.

We will discuss the interaction between phosphorous metabolism and carbohydrate metabolism and the possibility that worsening of insulin resistance could be related to adrug induced alteration in phosphorous metabolism, and the implications of that in medical management of diabetes and metabolic syndrome patients with mixed dyslipidemia.

【 授权许可】

   
2004 Al-Shaer and AbuSabha; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Physician desk reference (PDR) 2004.
• [2]Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH: Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990, 264:3013-3017.
• [3]The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360-381.
• [4]Data on file In Kos Pharmaceuticals, Inc. Weston FL;
• [5]Meyers CD, Kashyap ML: Management of the metabolic syndrome-nicotinic acid. Endocrinol Metab Clin North Am 2004, 33:557-575.
• [6]Kane MP, Hamilton RA, Addesse E, Busch RS, Bakst G: Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes. Pharmacotherapy 2001, 21:1473-1478.
• [7]Pan J, Lin M, Kesala RL, Van J, Charles MA: Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. Diabetes Obes Metab 2002, 4:255-261.
• [8]Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000, 284:1263-1270.
• [9]Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP, Diabetes Multicenter Research Group: Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002, 162:1568-1576.
• [10]Haglin L: Hypophosphataemia: cause of the disturbed metabolism in the metabolic syndrome. Med Hypotheses 2001, 56:657-663.
• [11]Guyton AC, Hall JE: Metabolism and temperature regulation in Textbook of Medical Physiology. 10th edition. WB Saunders Co; 778-780.
• [12]Haglin L, Lindblad A, Bygren LO: Hypophosphataemia in the metabolic syndrome. Gender differences in body weight and blood glucose. Eur J Clin Nutr 2001, 55:493-498.